Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 12/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | CASP1 | P29466 | 2/20 | 0.77 |
| ▸ | CASP7 | P55210 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16615188 | 1.00 | HPGD (0.81) | HPGDALDH1A1HSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL20467501 | 0.91 | HPGD (0.82) | HPGDALDH1A1HSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL4216921 | 0.91 | HPGD (0.98) | HPGDALDH1A1HSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL1718534 | 0.91 | HPGD (0.98) | HPGDALDH1A1HSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL20467331 | 0.91 | HPGD (0.82) | HPGDALDH1A1HSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL1718888 | 0.90 | HPGD (1.00) | HPGDALDH1A1HSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL4207439 | 0.90 | HPGD (0.83) | HPGDALDH1A1HSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL4216967 | 0.90 | HPGD (0.74) | HPGDALDH1A1HSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL4201038 | 0.90 | HPGD (0.81) | HPGDALDH1A1HSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL1719057 | 0.90 | HPGD (0.81) | HPGDALDH1A1HSD17B10SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020091-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR REDUCING GLIAL FIBRILLARY ACIDIC PROTEIN LEVELS | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-12 | — | — | US | disclosed |
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-12 | — | — | US | disclosed |
| US-20230310390-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING NEURODEGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-05 | — | — | US | disclosed |
| US-20230310390-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING NEURODEGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-05 | — | — | US | disclosed |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-08 | — | — | US | disclosed |
| US-20200095206-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-03-26 | — | — | US | disclosed |
| US-20190119282-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2019-04-25 | — | — | US | disclosed |
| WO-2018145080-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-08-09 | — | — | WO | disclosed |
| US-10030024-B2 | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030024-B2 | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160311825-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-10-27 | — | — | US | disclosed |
| US-20160311825-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-10-27 | — | — | US | disclosed |
| WO-2015048245-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310390-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING NEURODEGENERATION | GCDH, HPGD, HAGH | HPGD 2/4885ALDH1A1 86/4885HSD17B10 12/4885 |
| US-20200095206-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | HPGD, GCDH, HPGDS | HPGD 1/4885ALDH1A1 136/4885HSD17B10 21/4885 |
| US-20190119282-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, F2R, F2RL3 | HPGD 333/4885ALDH1A1 2459/4885HSD17B10 4235/4885 |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | HPGD, GCDH, HPGDS | HPGD 1/4885ALDH1A1 136/4885HSD17B10 21/4885 |
| US-20160311825-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, F2R, F2RL3 | HPGD 333/4885ALDH1A1 2459/4885HSD17B10 4235/4885 |
| US-10030024-B2 | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway | F2RL1, F2R, F2RL3 | HPGD 333/4885ALDH1A1 2459/4885HSD17B10 4235/4885 |
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | HPGD, GCDH, HPGDS | HPGD 1/4885ALDH1A1 136/4885HSD17B10 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.